Bioretec Completes 7.2 M€ Equity Funding Round

Bioretec´s investment round was oversubscribed and ended during the first subscription day.

”We are extremely delighted about the investors’ interest and trust towards our company and our innovative products. I would like to express my warmest gratitude to all the subscribers as well as to the professional team of Springvest for their work in coordinating and marketing of our investment round. We strongly believe that our products can provide considerable benefits to patients across the world – and accordingly this will lead into increased shareholder value”, summarizes Tomi Numminen, Bioretec´s Chairman of the Board of Directors.

The company focuses to the registration and commercialization of RemeOs™ trauma screws

”Our new production facilities are almost ready and RemeOs™ Screw registration process has been started with the U.S. FDA. The United States Food and Drug Administration FDA granted Breakthrough Device Designation for Bioretec’s bioresorbable RemeOs™ Screw and the on-going interactive process with the FDA forms a foundation to our registration process. We have a talented and motivated team and our groundbreaking pipeline consits of various next-generation bioresorbable products. We are accelerating forward to reach our operative targets”, comments Timo Lehtonen, CEO of the company.

Bioretec investment round was organized by Springvest Oy

”We have known Bioretec team extremely well already for years and wanted to organize this exciting investment round. We knew that Bioretec shares shall show strong demand  in the markets”, states Päivi Malinen, Springvest’s CEO.

SourceBioretec

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version